A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies	CD4+/CD56+ hematodermic neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, acute myeloid leukemia, aggressive systemic mastocytosis, bone marrow disorder, classic Hodgkin lymphoma, connective tissue neoplasm, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mastocytosis, myelodysplastic syndrome, myeloid leukemia, neoplasm, skin disorder, skin neoplasm	Active, not recruiting	Phase 1	2026-07-28		NCT05362773

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
MacroGenics	12

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Colorado Blood Cancer Network	Denver	United States	1
Dana Farber Cancer Institute	Boston	United States	300
Duke University Medical Center	Durham	United States	505
South Austin Medical Center	Austin	United States	2
START - Midwest	Grand Rapids	United States	1
University of Maryland, Greenbaum Comprehensive Cancer Center	Baltimore	United States	1
Washington University School of Medicine	St Louis	United States	895